Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

29.00 -1.32 (-4.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,846,957
Open 30.52
Bid (Size) 28.06 (1)
Ask (Size) 30.78 (1)
Prev. Close 30.32
Today's Range 28.93 - 30.54
52wk Range 14.56 - 32.13
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Biotech Breakout Will Be Led By Small Caps
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+35.58%
+35.58%
1 Month
+13.28%
+13.28%
3 Month
+29.52%
+29.52%
6 Month
+45.88%
+45.88%
1 Year
+31.88%
+31.88%

More News

Read More
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
From Denali Therapeutics Inc.
Via GlobeNewswire
4 Analysts Assess Denali Therapeutics: What You Need To Know
Via Benzinga
Denali Therapeutics: Q4 Earnings Insights
Via Benzinga
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Via InvestorPlace
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
From Denali Therapeutics Inc.
Via GlobeNewswire
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
To the Moon and Beyond: 7 Stocks With Cosmic Potential
Via InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces $500 million Private Placement Equity Financing
From Denali Therapeutics Inc.
Via GlobeNewswire
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.